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Background: Dystrobrevin binding protein 1 DTNBP1 is a schizophrenia susceptibility gene 
involved with neurotransmission regulation (especially dopamine and glutamate) and 
neurodevelopment. The gene is known to be associated with cognitive deficit phenotypes 
within schizophrenia. In our previous studies, DTNBP1 was found associated not only with 
schizophrenia but with other psychiatric disorders including psychotic depression, post-
traumatic stress disorder, nicotine dependence and opiate dependence. These findings suggest 
that DNTBP1 may be involved in pathways that lead to multiple psychiatric phenotypes. In 
this study we explored the association between DTNBP1 SNPs (single nucleotide 
polymorphisms) and multiple psychiatric phenotypes included in the Diagnostic Interview of 
Psychosis (DIP). 
Methods: Five DTNBP1 SNPs, rs17470454, rs1997679, rs4236167, rs9370822 and 
rs9370823 were genotyped in 235 schizophrenia subjects screened for various phenotypes in 
the domains of depression, mania, hallucinations, delusions, subjective thought disorder, 
behaviour and affect, and speech disorder. SNP-phenotype association was determined with 
ANOVA under general, dominant/recessive and over-dominance models. 
Results: Post-hoc tests determined that SNP rs1997679 was associated with visual 
hallucination; SNP rs4236167 was associated with general auditory hallucination as well as 
specific features including non-verbal, abusive and third-person form auditory hallucinations; 
and SNP rs9370822 was associated with visual and olfactory hallucinations. SNPs that 
survived correction for multiple testing were rs4236167 for third-person and abusive form 
auditory hallucinations; and rs9370822 for olfactory hallucinations. 
Conclusion: These data suggest that DTNBP1 is likely to play a role in development of 
auditory related, visual and olfactory hallucinations which is consistent with evidence of 
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DTNBP1 activity in the auditory processing regions, in visual processing and in the 
regulation of glutamate and dopamine activity. 






Schizophrenia is a highly heritable psychiatric disorder affecting approximately 1% of the 
population worldwide [1]. It has devastating consequences for those affected and their 
families and amounts to $19 billion of financial burden per annum in the USA [2]. 
Treatments targeting symptoms are only partially successful and there is limited 
understanding of schizophrenia aetiology. Progress in the understanding of the molecular 
aetiology of schizophrenia has been slow owing to the complex nature of the disorder and the 
heterogeneity of schizophrenia phenotypes. Early efforts focused on identifying 
schizophrenia susceptibility genes via case/control association studies. Results were often 
inconsistent or could not be replicated, perhaps because it is such a heterogeneous disorder. It 
is possible that clinically distinct forms of schizophrenia are the result of discrete 
combinations of susceptibility genes. Hence, this study is aimed at identifying the role that 
susceptibility genes play in specific clinical symptoms within schizophrenia rather than 
concentrating on the diagnosis of schizophrenia. 
 
Dystrobrevin binding protein 1 (DTNBP1) is a gene implicated in schizophrenia 
susceptibility. It encodes a protein that binds to alpha- and beta-dystrobrevin in muscle and 
brain [3]. Association studies have identified several DTNBP1 SNPs and haplotypes 
associated with negative symptoms of schizophrenia including poverty of speech, emotion, 
motivation and social interaction [4,5]. DTNBP1 mRNA expression is also reduced in the 
cortex and hippocampus of schizophrenia patients [6-8], suggesting that DTNBP1 plays a role 
in the aetiology of this disease perhaps by affecting brain development. Imaging studies have 
identified that DTNBP1 polymorphisms are associated with grey and white matter volume 
loss [9]. In rodents, DTNBP1 is highly expressed during embryonic stages [10,11] and 
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reduced DTNBP1 expression in cultured neurons leads to abnormal neuronal growth and 
dendritic morphology [10-13]. DTNBP1 has also been shown to play a role in 
neurotransmission by modulating the expression of two cell-surface receptor classes; the N-
methyl-D-aspartate receptor (NMDAR) [14] and the dopamine D2 receptor (DRD2) [15,16]. 
These findings suggest that DTNBP1 may play a role in the pathogenesis of schizophrenia by 
altering both brain development and neurotransmission activity. 
 
We have previously identified association of DTNBP1 SNPs with schizophrenia as well as 
several other psychiatric phenotypes [17-19]. These SNPs include one non-synonymous SNP 
rs17470454 (causing a proline to serine substitution) and four intronic SNPs rs1997679, 
rs4236167, rs9370822 and rs9370823. We found association between rs1997679, rs4236167, 
rs9370822, rs9370823 and schizophrenia in an Australian schizophrenia cohort (n = 160) [18] 
and the same SNPs were found associated with psychotic depression in a major depressive 
disorder cohort (n = 243) [17]. Interestingly, as well as schizophrenia, the DTNBP1 SNP 
rs9370822 was found associated with several other disorders including post-traumatic stress 
disorder (PTSD), nicotine dependence and opiate dependence but not alcohol dependence 
[19]. 
 
The objective of this study was to further explore the association between various psychiatric 
phenotypes in schizophrenia and DTNBP1 SNPs which have been found previously 







2.1.1 Schizophrenia patients 
The participants consist of 235 schizophrenia patients of European descent with a mean age 
of 43.9 years (s.d ± 10.7 years). There were 70 females and 165 males with a confirmed 
diagnosis of schizophrenia according to DSM-IV/ICD-10 diagnostic criteria with a mean 
onset age of 23.18 years (s.d ± 6.31 years). All participants underwent a clinical and 
neuropsychological assessment and provided a blood sample at the time of assessment.  The 
participants were assessed using a clinical assessment battery that consists of the Diagnostic 
Interview for Psychosis (DIP) [20] to collect clinical measures including depression, mania, 
hallucinations, subjective thought disorder, delusions, behaviour and affect, and speech 
disorder (Figure 1; details in Supplementary Table 1). The patients were recruited from 
several sources across five Australian States and Territories (New South Wales, Australian 
Capital Territory, Queensland, Western Australia and Victoria) using media advertisements, 
inpatient, outpatient and community mental health service providers, non-government 
organisations and rehabilitation services. 
 
2.1.2 Controls 
The control group was also obtained from the Australian Schizophrenia Research Bank.  The 
controls consisted of 121 females and 104 males of European descent, with a mean age of 
45.00 years (s.d. ± 13.2 years).  Healthy controls were screened for a family history of, or 
treatment for, a psychiatric illness at the time of registration.  The controls underwent a 
clinical and neuropsychological assessment and provided a blood sample at the time of 
assessment.  The controls were assessed using a clinical assessment battery that consists of 
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the Diagnostic Interview for Psychosis (DIP) [20] to collect socio-demographic, family and 
medical history data. 
 
2.1.3 Ethics 
Each participant gave written informed consent before commencement of data collection.  
Ethics approval for the project was obtained from the Human Research Ethics Committee of 
the Queensland University of Technology.  This study was carried out in accordance with 
The Code of Ethics of the World Medical Association (Declaration of Helsinki).   
 
2.2. SNP Genotyping 
Samples were genotyped for the DTNBP1 SNPs rs17470454, rs1997679, rs4236167, 
rs9370822 and rs9370823 essentially as previously described [18], using a homogeneous 
MassEXTEND (hME) Sequenom assay performed by the Australian Genome Research 
Facility. 
 
2.3. Statistical Analysis 
Clinical measures were analysed by ANOVA (analysis of variance) using Statistical Package 
for the Social Sciences (SPSS) 21 to detect score differences between genotypes under linear 
and quadratic models in schizophrenia patients. Clinical measure scores range from 0-2. A 
higher score means a higher clinical severity for a clinical measure. SNPs associated with 
general auditory hallucinations were further analysed for association with other forms 
(specific features) of auditory hallucinations. The genotypes were analysed under general, 
dominant/recessive and over-dominant models. Hardy-Weinberg equilibrium was tested 
using Utility Programs for Analysis of Genetic Linkage [21]. Correction for multiple testing 





DTNBP1 SNPs rs17470454, rs1997679, rs4236167,rs9370822 and rs9370823 were tested for 
association with schizophrenia followed by all clinical measures covered in the depression, 
mania, hallucinations, subjective thought disorder, delusions, behaviour and affect, and 
speech disorder domains (Supplementary table 1). All genotypes were found to be in Hardy-
Weinberg equilibrium (P > 0.05). All five SNPs were not associated with schizophrenia after 
comparing genotype frequencies of the five SNPs between schizophrenia patients and healthy 
controls. Clinical measure analysis revealed that the only domain to show consistent 
association was the hallucination domain. Multiple clinical measures within the hallucination 
domain were associated with DTNBP1 SNPs (Table 1). 
Retrospective power calculations determined that there was sufficient power (80%) to detect 
at least one hallucination phenotype for each SNP.  There was insufficient power to detect 
association with some hallucination phenotypes (as low as 1.78%, requiring a sample size up 
to 74622). No significant differences were detected between gender and hallucination 
measure scores. Risk genotypes for each SNP were determined using mean scores and post-
hoc pairwise comparisons between genotypes for the associated psychiatric measures 
(Figures 2-4).  
 
SNP rs17470454 was found associated with only one hallucination measure (olfactory 
hallucination) with a best-fit linear model. However, rs17470454 has a very low minor allele 
frequency and there was only one AA genotype count in our sample, hence rs17470454 was 




SNP rs1997679 was associated with visual hallucination with a best-fit quadratic model 
(Figure 2). Individuals with CC and CT genotypes had higher scores for visual hallucination 
compared to those with the TT genotype. Post-hoc Tukey’s test was also significant for CT 
versus TT genotypes (P = 0.023), suggesting that the C allele is inherited dominantly (P = 
0.025 when analysed as a C-dominant trait).  
 
SNP rs4236167 was associated with visual hallucination with a best-fit quadratic model and 
general auditory hallucination with neither best-fit model (Figure 3a). Further analysis of 
specific features of auditory hallucination (Table 2) also revealed SNP association with non-
verbal form auditory hallucination with best-fit linear and quadratic models, abusive form 
auditory hallucination with best-fit linear and quadratic models, and third-person form 
auditory hallucination with best-fit linear model (Figure 3b). For all auditory related 
hallucination measures, individuals with CC and CT genotypes had higher mean scores than 
those with the TT genotype. Post-hoc Tukey’s test was significant for general auditory 
hallucination (P = 0.040 for CT versus TT), non-verbal (P = 0.009 for CT versus TT), 
abusive (P = 0.003 for CT versus TT) and third-person form (P = 0.004 for CC versus TT; 
0.001 for CT versus TT) auditory hallucinations. These results suggest the C allele is likely a 
dominant allele for the auditory related hallucination phenotypes (P = 0.017 for general 
auditory hallucination, P = 0.003 for non-verbal form, P = 0.002 for abusive form and P = 
0.0001 for third-person form auditory hallucinations, when analysed as a C-dominant trait). 
For visual hallucination measure, heterozygote individuals had higher mean score than those 
who are homozygotes for both C and T allele. Post-hoc Tukey’s test was significant for CT 
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versus TT genotypes (P = 0.026). Visual hallucination mean scores and further analysis under 
a dominant model for rs4236167 (P = 0.004) suggests a dominant mode of inheritance. 
 
SNP rs9370822 was associated with visual hallucination with a best-fit quadratic model and 
olfactory hallucination with a best-fit quadratic model (Figure 4). Individuals with AA and 
AC genotypes had higher olfactory and visual hallucination scores than the CC genotype. 
Tukey’s test was significant between AC and CC genotypes for visual hallucination (P = 
0.025) and olfactory hallucination (P = 0.030), suggesting that the A allele is inherited 
dominantly for these clinical measures (P = 0.042 for visual hallucination, P = 0.006 for 
olfactory hallucination) under an A-dominant model.  
 
Associations that survived multiple testing correction were rs4236167 with third-person form 
auditory hallucination (P = 0.001, q = 0.010), rs4236167 with abusive form auditory 
hallucination (P = 0.005, q = 0.010), and rs9370822 with olfactory hallucination (P = 0.004, 
q = 0.0125). 
 
4. Discussion 
Following earlier findings of association between DTNBP1 SNPs and various cognitive 
phenotypes in schizophrenia [4-8,18,19,23-25], the current study explored the relationship 
between DTNBP1 SNPs and  schizophrenia phenotypes. We found that rs1997679, 
rs4236167 and rs9370822 were associated with various phenotypes within the hallucinations 
domain in an Australian schizophrenia cohort, especially for auditory related hallucinations. 
However, the functional role of rs1997679, rs4236167 and rs9370822 is still unclear. If any 
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of these SNPs are functional, it is likely that they are altering DTNBP1 expression by 
affecting gene splicing or transcription as they are all located intronically. Alternatively, they 
may simply be in disequilibrium with other functional DTNBP1 SNPs.  
 
One of the key features of schizophrenia is hallucinations. The dopamine and glutamate 
systems have been implicated in the development of hallucinations as drugs with strong 
dopaminergic effect and glutamate antagonists are known to induce hallucinations [26]. 
DTNBP1 has been reported to be involved in impaired visual processing function and 
reduced occipital lobe volume in schizophrenia patients [27,28]. The role of DTNBP1 in 
visual processing, along with its role in glutamate and dopamine neurotransmission suggests 
that DTNBP1 plays a key role in the pathogenesis and development of hallucinations. 
 
To our knowledge, no extant study has reported the association of DTNBP1 SNPs with 
hallucination phenotypes. Previous association studies emphasised the relationship between 
DTNBP1 SNPs and cognitive related phenotypes including executive function deficits, 
processing speed reduction and working memory deficits [4,5,23]. Association studies are 
also supported by reports that schizophrenia individuals with poorer cognitive performance 
have reduced DTNBP1 levels in the prefrontal cortex and hippocampal formation pertaining 
executive and working memory functions [6-8,24,25]. Mouse studies have also demonstrated 
that heterozygous and homozygous DTNBP1 knockout mice display schizophrenia-like 
cognitive deficits.  As well as reduced DTNBP1 mRNA levels, knockout mice have 
decreased glutamate release and decreased glutamate receptor function in the hippocampal 




It has been demonstrated that PCP (phencyclidine) exhibits antagonistic effects on NMDARs 
and use of PCP causes schizophrenia-like symptoms including positive symptoms, negative 
symptoms, and cognitive deficits [32]. Therefore, the glutamate system is believed to mediate 
multiple psychophysiological processes not limited to cognitive processes. Subsequent 
pharmacological models linking glutamate system hypofunctioning and schizophrenia-like 
symptoms (which include cognitive deficits as well as hallucinations) have been developed 
[33,34]. Considering DTNBP1 has a functional role in glutamate release [31,35], it is possible 
that DTNBP1 may also play a role in the pathogenesis of multiple psychiatric phenotypes 
including hallucinations (as found in the present study). 
 
SNP rs17470454 is a non-synonymous SNP causing a Pro191Ser substitution. One study 
reported marginal association between rs17470454 and bipolar disorder at the allele level 
[36]. The present study detected a dominant association between the A allele and olfactory 
hallucination. However, there is no evidence in the literature that could explain the biological 
significance of rs17470454 found associated to the identified hallucination phenotypes. 
 
It is known that levels of DTNBP1 mRNA are lower in various brain regions in 
schizophrenia, including the hippocampus and the superior temporal gyrus (STG) [6,8]. The 
hippocampus is involved in working memory [37] as hippocampus volume reduction has 
been significantly correlated with the degree of executive function and memory deficits [38-
41]. The STG plays a role in processing auditory information as it consists of the primary 
auditory cortex, auditory belt and the auditory parabelt [42-44]. Reduction in STG volume 
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has been found associated with the severity of auditory hallucinations [45-48]. It is possible 
that rs1997679, rs4236167 and rs9370822 play a role in the pathogenesis of auditory 
hallucinations due to their influence on DTNBP1 expression in brain regions affected in 
schizophrenia. DTNBP1 may be implicated in visual hallucinations as DTNBP1 risk 
haplotype has been reported in schizophrenia patients with impaired visual processing and 
reduced occipital lobe volume [27,28]. The abundant expression of glutamate and dopamine 
receptors in the olfactory epithelium [49] also suggests that DTNBP1 may have a role in 
olfactory hallucination due to the influence of DTNBP1 on glutamate and dopamine activity. 
 
The SNPs investigated in the present study differed from DTNBP1 SNPs found associated 
with cognitive deficits in many previous studies [23,50-58] (including intronic variants 
rs2619539, rs3213207, rs1011313, rs2619528, rs760761, rs2619522, rs1018381, and 
rs909706). The three associated SNPs in the present study are also intronic (rs1997679 
located ~4kb downstream of exon 1; rs4236167 located ~320bp upstream of 3’ –ag intron 
end; rs9370822 located ~11kb upstream of exon 8) but not in close proximity to the “gt-” nor 
“-ag” splicing consensus. The three SNPs are situated within clusters of DNase 
hypersensitive sites according to the ENCODE genome browser 
(http://genome.ucsc.edu/ENCODE/). According to HapMap, SNPs rs1997679 and 
rs9370822, but not rs4236167, are in linkage disequilibrium with a functional SNP 
(rs1047631) where the A allele was reported to reduce DTNBP1 mRNA [59]. This suggests a 
possibility that the association found with rs1997679 and rs9370822 may be due to strong 
linkage disequilibrium with the functional SNP rs1047631. SNP rs4236167 however, may be 
in linkage disequilibrium with another unknown functional SNP, or may be functional itself 
due to its location within a DNase hypersensitive site which may influence the transcriptional 




The finding of association between DTNBP1 SNPs and auditory hallucinations suggests that 
hypofunction of DTNBP1 in brain regions that process auditory information may be 
responsible for the development of auditory hallucinations. Unlike the association between 
DTNBP1 and cognitive impairment, there is lack of direct evidence in the literature to support 
the association between DTNBP1 and hallucinations. A plausible alternative explanation for 
our findings is that hallucinations may be a secondary phenotype caused by visual as well as 
cognitive impairment. One study found that auditory and visual hallucinations were 
associated with lower cognitive baseline and rapid cognitive decline in Alzheimer’s disease 
[60]. The positive association between the DTNBP1 SNPs and hallucinations found in the 
present study may be due to the presence of visual and cognitive impairment which may be 
the primary cause of hallucinations, especially visual and auditory hallucinations. 
 
In addition to the association of DTNBP1 variants with cognitive deficits, we conclude that 
rs1997679 is associated with visual and auditory related hallucinations; rs4236167 is 
associated with auditory related hallucinations; and rs9370822 is associated with visual, 
olfactory and auditory related hallucinations. 
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Table 1: Genotype association of five DTNBP1 SNPs with various clinical measures of schizophrenia. 
   Hallucination measure mean scores
a 
SNP Genotypes Visual Olfactory Auditory 
rs17470454 
AA 2.00 (1) 2.00 (1) 2.00 (1) 
AG 0.82 (22) 0.59 (22) 1.50 (22) 
GG 0.85 (168) 0.25 (167) 1.36 (168) 
 P = 0.409 P = 0.001 P = 0.557 
rs1997679 
CC 0.80 (99) 0.30 (99) 1.34 (99) 
CT 1.01 (78) 0.28 (78) 1.49 (78) 
TT 0.36 (14) 0.31 (13) 1.00 (14) 
  P = 0.021 P = 0.971 P = 0.102 
rs4236167 
CC 0.71 (49) 0.17 (48) 1.41 (49) 
CT 1.04 (89) 0.37 (89) 1.49 (83) 
TT 0.66 (53) 0.28 (53) 1.15 (53) 
  P = 0.015 P = 0.160 P = 0.050 
rs9370822 
AA 0.77 (71) 0.26 (70) 1.45 (71) 
AC 1.04 (83) 0.43 (83) 1.41 (83) 
CC 0.59 (37) 0.05 (37) 1.16 (37) 
  P = 0.021 P = 0.004 P = 0.196 
rs9370823 
AA 0.81 (100) 0.29 (99) 1.39 (100) 
AG 1.01 (70) 0.36 (70) 1.41 (70) 
GG 0.52 (21) 0.10 (21) 1.19 (21) 
  P = 0.056 P = 0.213 P = 0.534 




Table 2: Genotype association of rs4236167 with specific features of auditory hallucinations. 
  Specific features of auditory hallucination mean scores 
Genotypes Nonverbal Abusive Commentary Thirdperson 
CC 0.70 (47) 1.13 (53) 0.58 (53) 0.81 (53) 
CT 0.80 (89) 1.27 (101) 0.50 (101) 0.79 (101) 
TT 0.36 (53) 0.78 (55) 0.44 (55) 0.29 (55) 





Figure 1: DIP clinical measures used for assessment of schizophrenia patients. 
 
Figure 2: Mean hallucination scores for DTNBP1 rs1997679 genotypes. 
* indicates post-hoc Tukey’s P < 0.05 compared with the genotype with lowest score. Error 
bars indicate ±SD. 
 
Figure 3a: Mean hallucination scores for DTNBP1 rs4236167 genotypes. 
* indicates post-hoc Tukey’s P < 0.05 compared with the genotype with lowest score, ** 
indicates post-hoc Tukey’s P < 0.01 compared with the genotype with lowest score. Error 
bars indicate ±SD. 
 
Figure 3b: Mean hallucination specific feature scores for DTNBP1 rs4236167 genotypes. 
** indicates post-hoc Tukey’s P < 0.01 compared with the genotype with lowest score. Error 
bars indicate ±SD. 
 
Figure 4: Mean hallucination scores for DTNBP1 rs9370822 genotypes. 
* indicates post-hoc Tukey’s P < 0.05 compared with the genotype with lowest score. Error 
bars indicate ±SD. 
 
